Lexeo Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 11, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 11, 2024
LXEO$3.06-2.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Shareholders’ Equity (Deficit)
Consolidated Statements of Convertible Preferred Stock and Stockholders’ Equity (Deficit)
(In thousands, except share amounts)
| Convertible · Additional · Total | |||||||
|---|---|---|---|---|---|---|---|
| Preferred Stock · Common Stock · Paid-in · Accumulated · Stockholders' | |||||||
| Shares | Amount | Shares | Amount | Capital | Deficit | Equity (Deficit) | |
| Balances at December 31, 2021 | 143,653,545 | $185,013 | 1,580,651 | $— | $567 | $(56,169) | $(55,602) |
| Proceeds from issuance of series A convertible preferred stock | — | 20 | — | — | — | — | — |
| Exercise of stock options | — | — | 68,083 | — | 332 | — | 332 |
| Proceeds received from early exercise of unvested stock options subject to repurchase and recorded as deposit liabilities, net of amounts reclassified from deposit liabilities upon the vesting of early-exercised stock options previously subject to repurchase | — | — | (41,549) | — | (188) | — | (188) |
| Stock-based compensation expense | — | — | — | — | 1,781 | — | 1,781 |
| Net loss | — | — | — | — | — | (59,277) | (59,277) |
| Balances at December 31, 2022 | 143,653,545 | $185,033 | 1,607,185 | $— | $2,492 | $(115,446) | $(112,954) |
| Exercise of stock options | — | — | 11,916 | — | 51 | — | 51 |
| Amounts reclassified from deposit liabilities upon the vesting of early-exercised stock options previously subject to repurchase, net of proceeds received from early exercise of unvested stock options subject to repurchase and recorded as deposit liabilities | — | — | 19,442 | — | 87 | — | 87 |
| Conversion of SAFE Note into common stock in connection with initial public offering, net of issuance costs of $113 | — | — | 411,815 | — | 4,417 | — | 4,417 |
| Issuance of common stock upon initial public offering and subsequent partial exercise of underwriters' option to purchase additional shares, net of underwriting discounts, commissions and offering costs of $11,285 | — | — | 10,139,656 | 1 | 100,250 | — | 100,251 |
| Conversion of convertible preferred stock into common stock in connection with initial public offering, net of issuance costs of $519 | (143,653,545) | (185,033) | 14,456,364 | 2 | 185,032 | — | 185,034 |
| Stock-based compensation expense | — | — | — | — | 3,043 | — | 3,043 |
| Net loss | — | — | — | — | — | (66,394) | (66,394) |
| Balances at December 31, 2023 | — | — | 26,646,378 | $3 | $295,372 | $(181,840) | $113,535 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.